ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
Background: Inhibiting proliferation and inducing apoptosis of myofibroblasts is becoming one of the promising and effective ways to treat hypertrophic scar. ABT-263, as an orally bioavailable BCL-2 family inhibitor, has showed great antitumor characteristics by targeting tumor cell apoptosis. The o...
Main Authors: | , , , , , , |
---|---|
פורמט: | Article |
שפה: | English |
יצא לאור: |
Frontiers Media S.A.
2021-01-01
|
סדרה: | Frontiers in Pharmacology |
נושאים: | |
גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fphar.2020.615505/full |